FM
SNDX icon

Frazier Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Frazier Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,772,062
Closed -$60.7M – 25
2021
Q4 		$60.7M Buy
2,772,062
+1,583,927
+133% +$29.3M 4.67% 4
2021
Q3 		$22.7M Hold
1,188,135
– – 1.82% 17
2021
Q2 		$20.4M Sell
1,188,135
-246,910
-17% -$4.52M 1.88% 13
2021
Q1 		$32.1M Buy
1,435,045
+30,000
+2% +$678K 2.57% 11
2020
Q4 		$31.2M Buy
1,405,045
+85,000
+6% +$1.76M 2.41% 12
2020
Q3 		$19.5M Hold
1,320,045
– – 1.75% 13
2020
Q2 		$19.6M Buy
1,320,045
+329,334
+33% +$5.02M 1.72% 13
2020
Q1 		$10.9M Buy
+990,711
New +$9.3M 1.23% 12

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Frazier Management's SNDX Position: Q1 2022 in Review

Frazier Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2022, closing a stake of 2,772,062 shares — an estimated $60.7M sold.

Frazier Management first reported a position in SNDX in Q1 2020 and held it in 8 quarters. The position peaked at $60.7M in Q4 2021. 136 funds tracked by Wall St. Rank hold SNDX as of Q1 2022.

  • Frazier Management reported no remaining Syndax Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 2,772,062 Syndax Pharmaceuticals shares in Q1 2022, an estimated $60.7M.
  • Frazier Management first reported a position in Syndax Pharmaceuticals in Q1 2020 and held it in 8 quarters.
  • Frazier Management's Syndax Pharmaceuticals position peaked at $60.7M in Q4 2021.
  • 136 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.